
    
      Eligible subjects will be admitted on Day -2 and remain confined on the unit for 20 days.
      Each subject will receive a single dose of study drug per the defined treatment periods on
      the morning of Day 1, Day 8 and Day 15. There will be a minimum of 7 days between each
      consecutive dose group.

      For Treatment A, Formulation 1 tablets will be administered within 30 minutes after the start
      of a standard FDA moderate-fat breakfast. Treatment B, Formulation 2 tablets will be
      administered in a fasted state. For Treatment C, Formulation 2 tablets will be administered
      within 30 minutes after the start of a standard FDA moderate-fat breakfast.

      Any subject discontinuing the study prior to completion should have all end of study
      evaluations completed
    
  